| __timestamp | Amphastar Pharmaceuticals, Inc. | BioMarin Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 159205000 | 129764000 |
| Thursday, January 1, 2015 | 174172000 | 152008000 |
| Friday, January 1, 2016 | 150976000 | 209620000 |
| Sunday, January 1, 2017 | 149380000 | 241786000 |
| Monday, January 1, 2018 | 187681000 | 315264000 |
| Tuesday, January 1, 2019 | 190434000 | 359466000 |
| Wednesday, January 1, 2020 | 206506000 | 524272000 |
| Friday, January 1, 2021 | 238029000 | 470515000 |
| Saturday, January 1, 2022 | 250127000 | 483669000 |
| Sunday, January 1, 2023 | 293274000 | 577065000 |
| Monday, January 1, 2024 | 580235000 |
Unveiling the hidden dimensions of data
In the ever-evolving landscape of pharmaceuticals, understanding cost structures is pivotal. This analysis delves into the cost of revenue trends for BioMarin Pharmaceutical Inc. and Amphastar Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, BioMarin's cost of revenue surged by approximately 345%, reflecting its aggressive expansion and increased production capabilities. In contrast, Amphastar's costs rose by about 84%, indicating a more measured growth strategy.
BioMarin's cost of revenue peaked in 2023, reaching nearly 5.8 times its 2014 value, showcasing its commitment to innovation and market expansion. Meanwhile, Amphastar's costs, though rising steadily, highlight a focus on efficiency and cost management. This comparative analysis offers a window into the strategic priorities of these pharmaceutical giants, providing valuable insights for investors and industry analysts alike.
Cost of Revenue: Key Insights for AbbVie Inc. and BioMarin Pharmaceutical Inc.
Cost of Revenue Trends: Novartis AG vs Amphastar Pharmaceuticals, Inc.
Bristol-Myers Squibb Company vs BioMarin Pharmaceutical Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Zoetis Inc. vs BioMarin Pharmaceutical Inc.
Analyzing Cost of Revenue: GSK plc and BioMarin Pharmaceutical Inc.
Analyzing Cost of Revenue: Biogen Inc. and BioMarin Pharmaceutical Inc.
Analyzing Cost of Revenue: United Therapeutics Corporation and Amphastar Pharmaceuticals, Inc.
BioMarin Pharmaceutical Inc. vs Jazz Pharmaceuticals plc: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Corcept Therapeutics Incorporated
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and MorphoSys AG
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and HUTCHMED (China) Limited
Jazz Pharmaceuticals plc vs Amphastar Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored